Pretreatment Of Plasma For Spray Drying And Storage

Patent metadata

Field	Value
Publication number	US-2024091155-A1
Application number	US-202217945126-A
Country	US
Kind code	A1
Filing date	Sep 15, 2022
Priority date	Sep 15, 2022
Publication date	Mar 21, 2024
Grant date	—

Abstract

A method of treating plasma with a pretreatment solution that has a physiologically compatible spray dry stable acidic substance (SDSAS) and an amino acid, prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compositions related to plasma dried by the methods of the present invention.

First claim

What is claimed is:

1 ) A method of producing spray dried plasma, the method comprising the steps of:
a) combining plasma with a pretreatment solution, wherein the pretreatment solution comprises
i) glycine in an amount ranging between about 50 μmole/mL of plasma and about 110 μmole/mL of plasma, and
ii) hydrochloric acid (HCl) in an amount ranging between about 10 μmole/mL of plasma and about 30 μmole/mL of plasma,
to thereby obtain formulated plasma; and

b) drying the formulated plasma with a spray drying system to create spray dried formulated plasma,
wherein when the spray dried formulated plasma is reconstituted, an amount of von Willebrand factor (vWf) recovered in the reconstituted plasma is increased, an amount of C5a in the reconstituted plasma is reduced, or both, as compared to plasma not subjected to step a.

2 ) The method of claim 1 , wherein the pretreatment solution comprises glycine in an amount ranging between about 70 μmole/mL of plasma and about 90 μmole/mL of plasma.

3 ) The method of claim 2 , wherein the pretreatment solution comprises glycine in an amount of about 84 μmole/mL of plasma.

4 ) The method of claim 1 , wherein the pretreatment solution comprises HCl in an amount ranging between about 15 μmole/mL of plasma and about 25 μmole/mL of plasma.

5 ) The method of claim 1 , wherein the pretreatment solution comprises HCl in an amount of about μmole/mL of plasma.

6 ) The method of claim 1 , wherein the molar ratio of glycine to HCl is between about 1.5 and 8.

7 ) The method of claim 5 , wherein the molar ratio of glycine to HCl is between about 2 and 6.

8 ) The method of claim 6 , wherein the molar ratio of glycine to HCl is between about 4.15.

9 ) The method of claim 1 , wherein the pH of the pretreatment solution is between about 2.0 and about 4.0.

10 ) The method of claim 9 , wherein said formulated plasma of step a) has a pH of about 6.0 to about 6.6.

11 ) The method of claim 1 , further comprising the step of reconstituting the spray dried formulated plasma with a reconstitution solution to produce reconstituted plasma.

12 ) The method of claim 11 , wherein said reconstituted plasma has a pH of about 6.7 to about 7.8.

13 ) The method of claim 11 , further comprising selecting a subject in need of plasma transfusion and transfusing said reconstituted plasma

14 ) The method of claim 1 , wherein a first volume of said plasma is rapidly added to a second volume of the pretreatment solution to thereby obtain a formulated plasma, wherein the second volume is about 30% or less of the first volume.

15 ) The method of claim 1 , wherein the method further comprises agitating the formulated plasma prior to step b).

16 ) The method of claim 1 , wherein the amount of C5a is between about 0.1 to about 30 ng/mL.

17 ) The method of claim 16 , wherein the amount of C5a is between about 8 to about 12 ng/mL.

18 ) The method of claim 1 , wherein the amount of C5a is within 20% of that in never frozen plasma.

19 ) The method of claim 18 , wherein the amount of C5a is within 10% of that in never frozen plasma.

20 ) The method of claim 19 , wherein the amount of C5a is within 5% of that in never frozen plasma.

21 ) The method of claim 1 , wherein said recovery of active von Willebrand factor is of about 5 to about 40 percentage points greater than the recovery of active von Willebrand factor obtained from an otherwise identical spray dried plasma that has not undergone formulation with glycine and HCl.

22 ) The method of claim 21 , wherein said recovery of active von Willebrand factor is of about 10 to about 35 percentage points greater than the recovery of active von Willebrand factor obtained from an otherwise identical spray dried plasma that has not undergone formulation with glycine and HCl.

23 ) A reconstituted formulated plasma product for human transfusion, wherein dried formulated plasma is reconstituted with water, the reconstituted formulated plasma product has a pH that is within 10% of preformulated plasma.

24 ) The reconstituted formulated plasma product of claim 23 , wherein the reconstituted formulated plasma product has a pH of about 6.7 to about 7.8

25 ) The reconstituted formulated plasma product of claim 23 , wherein the reconstituted formulated plasma product has a pH of about 6.9 and 7.2.

26 ) The reconstituted formulated plasma product of claim 23 , wherein the reconstituted formulated plasma product comprises an amount of C5a in a range between about 0.1 to about 30 ng/mL.

27 ) The reconstituted formulated plasma product of claim 23 , wherein the reconstituted formulated plasma product is formulated by combining plasma with a pretreatment solution comprising one or more physiologically compatible spray dry stable acidic substance (SDSAS) in an amount between about 1 mM and about 50 mM and one or more amino acids in an amount of about 50 mM and about 100 mM to thereby obtain formulated plasma.

28 ) The reconstituted formulated plasma product of claim 27 , wherein the reconstituted formulated plasma product is dried with a spray drying system.

29 ) A formulated spray dried plasma product for human transfusion, wherein when the formulated dried formulated plasma product is reconstituted with water, the reconstituted formulated plasma product has a pH that is within 10% of preformulated plasma

30 ) The formulated spray dried plasma product for human transfusion of claim 29 , wherein the reconstituted formulated plasma product has a pH of about 6.7 to about 7.8

31 ) The formulated spray dried plasma product for human transfusion of claim 29 , wherein the reconstituted formulated plasma product has a pH of about 6.9 and 7.2.

32 ) The formulated spray dried plasma product for human transfusion of claim 29 , wherein the reconstituted formulated plasma product comprises an amount of C5a in a range between about 0.1 to about 30 ng/mL.

33 ) The formulated spray dried plasma product for human transfusion of claim 29 , wherein the formulated spray dried plasma product is formulated by combining plasma with a pretreatment solution comprising one or more physiologically compatible spray dry stable acidic substance (SDSAS) in an amount between about 1 mM and about 50 mM and one or more amino acids in an amount of about 50 mM and about 100 mM in the formulated plasma.

34 ) The formulated spray dried plasma product for human transfusion of claim 29 , wherein the reconstituted formulated plasma product is dried with a spray drying system.

35 ) A spray dried plasma product for human transfusion, the spray dried plasma product having been formulated such when reconstituted with water to a volume equal to the source plasma, has a pH of about 6.7 to about 7.8 and comprises an amount of C5a in a range between about 0.1 to about 30 ng/mL upon reconstitution.

36 ) A spray dried plasma product obtained by the steps of:
a) combining plasma with a pretreatment solution comprising one or more physiologically compatible spray dry stable acidic substance (SDSAS) in a final amount between about 1 mM to about 50 mM and one or more amino acids in an amount of about 50 mM and about 100 mM to thereby obtain formulated plasma; and b) d

Assignees

• Velico Medical Inc

Inventors

• Liu Qiyong Peter
• Merritt William J
• Sohn Jihae

Classifications

• F26B3/12 Primary

  in the form of a spray {, i.e. sprayed or dispersed emulsions or suspensions (spray drying of solutions B01D1/18)} · CPC title

• B01D1/16

  by spraying (B01D1/22 takes precedence) · CPC title

• A61K35/16

  Blood plasma; Blood serum (umbilical cord blood A61K35/51) · CPC title

• A61K9/1682 Primary

  Processes · CPC title